185 related articles for article (PubMed ID: 27234586)
1. Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine.
Bhutia YD; Babu E; Ganapathy V
Biochem J; 2016 Jun; 473(11):1503-6. PubMed ID: 27234586
[TBL] [Abstract][Full Text] [Related]
2. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of antineoplastic activity of lonidamine.
Nath K; Guo L; Nancolas B; Nelson DS; Shestov AA; Lee SC; Roman J; Zhou R; Leeper DB; Halestrap AP; Blair IA; Glickson JD
Biochim Biophys Acta; 2016 Dec; 1866(2):151-162. PubMed ID: 27497601
[TBL] [Abstract][Full Text] [Related]
4. Correspondence re: M. Fanciulli et al., Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence fo lonidamine. Clin. Cancer Res., 6: 1590-1597, 2000.
Kaplan O
Clin Cancer Res; 2000 Oct; 6(10):4166-7. PubMed ID: 11051272
[No Abstract] [Full Text] [Related]
5. Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment.
Miccoli L; Poirson-Bichat F; Sureau F; Bras Gonçalves R; Bourgeois Y; Dutrillaux B; Poupon MF; Oudard S
J Natl Cancer Inst; 1998 Sep; 90(18):1400-6. PubMed ID: 9747871
[TBL] [Abstract][Full Text] [Related]
6. [Targeting the gene of glucose metabolism for the treatment of advanced gliomas].
Oudard S; Miccoli L; Dutrillaux B; Poupon MF
Bull Cancer; 1998 Jul; 85(7):622-6. PubMed ID: 9752269
[TBL] [Abstract][Full Text] [Related]
7. The mitochondrial voltage-dependent anion channel 1 in tumor cells.
Shoshan-Barmatz V; Ben-Hail D; Admoni L; Krelin Y; Tripathi SS
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2547-75. PubMed ID: 25448878
[TBL] [Abstract][Full Text] [Related]
8. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
[TBL] [Abstract][Full Text] [Related]
9. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.
Floridi A; Paggi MG; D'Atri S; De Martino C; Marcante ML; Silvestrini B; Caputo A
Cancer Res; 1981 Nov; 41(11 Pt 1):4661-6. PubMed ID: 7306982
[TBL] [Abstract][Full Text] [Related]
10. Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.
Silvestrini B; Hahn GM; Cioli V; De Martino C
Br J Cancer; 1983 Feb; 47(2):221-31. PubMed ID: 6824568
[TBL] [Abstract][Full Text] [Related]
11. Effect of lonidamine on the aerobic glycolysis of normal and phytohemagglutinin-stimulated human peripheral blood lymphocytes.
Nista A; De Martino C; Malorni W; Marcante ML; Silvestrini B; Floridi A
Exp Mol Pathol; 1985 Apr; 42(2):194-205. PubMed ID: 3156759
[TBL] [Abstract][Full Text] [Related]
12. Lonidamine in malignant brain tumors.
Schiffer D; Sales S; Soffietti R
Semin Oncol; 1991 Apr; 18(2 Suppl 4):38-41. PubMed ID: 2031197
[TBL] [Abstract][Full Text] [Related]
13. An update on therapeutic opportunities offered by cancer glycolytic metabolism.
Granchi C; Fancelli D; Minutolo F
Bioorg Med Chem Lett; 2014 Nov; 24(21):4915-25. PubMed ID: 25288186
[TBL] [Abstract][Full Text] [Related]
14. Lonidamine, a new approach to cancer therapy.
Caputo A; Silvestrini B
Oncology; 1984; 41 Suppl 1():2-6. PubMed ID: 6371644
[TBL] [Abstract][Full Text] [Related]
15. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells.
Fanciulli M; Valentini A; Bruno T; Citro G; Zupi G; Floridi A
Oncol Res; 1996; 8(3):111-20. PubMed ID: 8823807
[TBL] [Abstract][Full Text] [Related]
16. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
Cervantes-Madrid D; Romero Y; Dueñas-González A
Biomed Res Int; 2015; 2015():690492. PubMed ID: 26425550
[TBL] [Abstract][Full Text] [Related]
17. Lonidamine in metastatic breast cancer.
Rosso R; Amoroso D; Gardin G; Miglietta L; Guido T; Pace M; Repetto L; Pronzato P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):62-5. PubMed ID: 2031200
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of Lonidamine in patients with advanced malignancy.
Evans WK; Shepherd FA; Mullis B
Oncology; 1984; 41 Suppl 1():69-77. PubMed ID: 6717899
[TBL] [Abstract][Full Text] [Related]
19. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
Calviño E; Estañ MC; Simón GP; Sancho P; Boyano-Adánez Mdel C; de Blas E; Bréard J; Aller P
Biochem Pharmacol; 2011 Dec; 82(11):1619-29. PubMed ID: 21889928
[TBL] [Abstract][Full Text] [Related]
20. Morphological effects of lonidamine on two human-tumor cell culture lines.
Szekely JG; Lobreau AU; Delaney S; Raaphorst GP; Feeley M
Scanning Microsc; 1989 Jun; 3(2):681-91; discussion 691-3. PubMed ID: 2814409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
